Zai Lab (ZLAB) said late Wednesday that China's National Medical Products Administration has accepted its marketing application for Tivdak, a therapy for treating certain patients with cervical cancer.
The company said the application is supported by a phase 3 study in which Tivdak demonstrated a 45% reduction in the risk of death compared to chemotherapy in the China subpopulation that had received prior standard systemic therapies.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。